Add-on Acquisition • Life Science

ArQule Acquires Cyclis Pharmaceuticals

On July 17, 2003, ArQule acquired life science company Cyclis Pharmaceuticals for 25M USD

Acquisition Context

This is ArQule’s 2nd transaction in the Life Science sector.
This is ArQule’s 2nd largest (disclosed) transaction.
This is ArQule’s 2nd transaction in the United States.
This is ArQule’s 1st transaction in Massachusetts.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	July 17, 2003
Target	Cyclis Pharmaceuticals
Sector	Life Science
Buyer(s)	ArQule
Deal Type	Add-on Acquisition
Deal Value	25M USD

Target Company

Cyclis Pharmaceuticals

Norwood, Massachusetts, United States

Cyclis is discovering and developing small-molecule cancer drugs based on a novel technology designed to selectively kill cancer cells and preserve normal cells by restoring and activating cellular checkpoints known to be defective in cancers.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

ArQule

Burlington, Massachusetts, United States

Category	Company
Founded	1993
Sector	Life Science
Employees	38
Revenue	26M USD (2018)

DESCRIPTION

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. ArQule's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule was formed in 1993 and is based in Burlington, Massachusetts.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
State: Massachusetts	1 of 1
Country: United States	2 of 2
Year: 2003	1 of 1
Size (of disclosed)	2 of 2

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2001-01-29	Camitro Menlo Park, California, United States Camitro Corp., is a predictive modeling company. Camitro's technology consisted of an integrated platform of predictive models and strategies for the design, selection, and optimization of potential new pharmaceutical drugs.	Buy	$76M

DATE

TARGET

DEAL TYPE

VALUE

2001-01-29

Camitro

Menlo Park, California, United States

Camitro Corp., is a predictive modeling company. Camitro's technology consisted of an integrated platform of predictive models and strategies for the design, selection, and optimization of potential new pharmaceutical drugs.

Buy

$76M

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Massachusetts M&A - United States M&A - 2003 M&A